TARDBP and amyotrophic lateral sclerosis: Similarly, our use of the MSD platform in the quantification of full-length TDP-43 in biofluids will be a valuable tool to measure levels in many neurodegenerative diseases and evaluate alterations due to pathophysiologic changes in TDP-43 and responses to treatments that target TDP-43 in ALS as well as other TDP-43 proteinopathies.